{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:37Z","timestamp":1787440957752,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003562","name":"Ministry of Environment","doi-asserted-by":"publisher","award":["2026-RISE-17\\u2013001"],"award-info":[{"award-number":["2026-RISE-17\\u2013001"]}],"id":[{"id":"10.13039\/501100003562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025\\u201321212975"],"award-info":[{"award-number":["RS-2025\\u201321212975"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119443","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:27:36Z","timestamp":1778754456000},"page":"119443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacologic activation of PHD2 sensitizes non\u2013small cell lung cancer cells to osimertinib"],"prefix":"10.1016","volume":"200","author":[{"given":"Ji Soo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0758-2042","authenticated-orcid":false,"given":"Hiruni Nilshi Indeevarie","family":"Abeysiriwardhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0812-1826","authenticated-orcid":false,"given":"Dae Kyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5432-0679","authenticated-orcid":false,"given":"Tae Hyeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1681-829X","authenticated-orcid":false,"given":"Zhuoning","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-5594","authenticated-orcid":false,"given":"Kwang-Hyeon","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoongho","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0980-2005","authenticated-orcid":false,"given":"Somi Kim","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonjae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119443_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119443_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of Non-Small-Cell Lung Cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.biopha.2026.119443_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stem.2024.03.008","article-title":"Patient-derived tumor-like cell clusters for personalized chemo-and immunotherapies in non-small cell lung cancer","volume":"31","author":"Yin","year":"2024","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.biopha.2026.119443_bib4","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s12325-024-02799-9","article-title":"Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: A systematic literature review","volume":"41","author":"Khasraw","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2026.119443_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-025-03139-6","article-title":"Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies: Genetics and Genomics","volume":"133","author":"Rocca","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119443_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.21037\/tlcr-2025-60","article-title":"Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations","volume":"14","author":"Yang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.biopha.2026.119443_bib7","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib8","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119443_bib9","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"NeoADAURA Investigators, Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119443_bib12","article-title":"Overcoming resistance to osimertinib by T790M loss and C797S acquisition using gefitinib in a patient with EGFR-mutant NSCLC: A case report","volume":"4","author":"Enrico","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.biopha.2026.119443_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: An overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.biopha.2026.119443_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000805","article-title":"Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer","volume":"34","author":"Zeng","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib15","series-title":"in: Seminars in radiation oncology","article-title":"Hypoxia as a cause of treatment failure in non\u2013small cell carcinoma of the lung","author":"Brustugun","year":"2015"},{"key":"10.1016\/j.biopha.2026.119443_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119443_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gene.2014.03.025","article-title":"Prognosis value of HIF-1\u03b1 expression in patients with non-small cell lung cancer","volume":"541","author":"Wang","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2026.119443_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lungcan.2010.08.005","article-title":"Prognostic implications of hypoxia-inducible factor-1\u03b1 in epidermal growth factor receptor-negative non-small cell lung cancer","volume":"72","author":"Park","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.biopha.2026.119443_bib19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13046-022-02522-y","article-title":"Targeting hypoxia in solid and haematological malignancies","volume":"41","author":"Harris","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119443_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.tibs.2025.06.005","article-title":"The HIF axes in cancer: Angiogenesis, metabolism, and immune-modulation","volume":"50","author":"Acu\u00f1a-Pilarte","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.biopha.2026.119443_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: Cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119443_bib22","series-title":"in: Seminars in Cancer Biology","article-title":"Hypoxia signaling and metastatic progression","author":"Schito","year":"2023"},{"key":"10.1016\/j.biopha.2026.119443_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: Implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.biopha.2026.119443_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbiomolbio.2025.05.003","article-title":"Advances in the mechanisms of HIF-1\u03b1-enhanced tumor glycolysis and its relation to dedifferentiation","volume":"197","author":"Zeng","year":"2025","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119443_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: Pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2026.119443_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/9077926","article-title":"Role of angiogenesis and its biomarkers in development of targeted tumor therapies","volume":"2024","author":"Pathak","year":"2024","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.biopha.2026.119443_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.218","article-title":"Metabolic reprogramming in cancer: Mechanisms and therapeutics","volume":"4","author":"Nong","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.biopha.2026.119443_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3892\/or.2024.8714","article-title":"Advances of HIF-1\u03b1\/glycolysis axis in non-small cell lung cancer","volume":"51","author":"Shi","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119443_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37739","article-title":"Exploring the prognostic and therapeutic value of HIF1A in lung adenocarcinoma","volume":"10","author":"Lu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119443_bib30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41598-020-79801-1","article-title":"High expression of hypoxia inducible factor 1\u03b1 related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC","volume":"11","author":"Jin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119443_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: From drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119443_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","article-title":"HIF-1\u03b1 signaling: Essential roles in tumorigenesis and implications in targeted therapies","volume":"11","author":"Zhao","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2026.119443_bib33","article-title":"The Interplay Between HIF-1\u03b1 and EZH2 in Lung Cancer and Dual-Targeted Drug Therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.biopha.2026.119443_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13765-022-00764-0","article-title":"Therapeutic effects of TMF and catechol in pulmonary fibrosis: In vitro and in vivo analysis","volume":"66","author":"Choi","year":"2023","journal-title":"Appl. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13765-025-01007-8","article-title":"Design, synthesis, and biological evaluation of ACF-03: A novel anti-fibrotic and antioxidant agent targeting ROS-TGF-\u03b21-HIF-1\u03b1 axis","volume":"68","author":"Abeysiriwardhana","year":"2025","journal-title":"Appl. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/mrc.5113","article-title":"1H and 13C NMR spectral assignment of 29 N\u2032-(3-([1,1\u2032-biphenyl]-4-yl)-1-phenyl-1H-pyrazol-4-yl)acylhydrazones","volume":"59","author":"Park","year":"2021","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/ml100198y","article-title":"Benzimidazole-2-pyrazole HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues","volume":"1","author":"Rosen","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119443_bib38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib40","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/prot.26541","article-title":"Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2\u03b1 to prolyl hydroxylase domain 2","volume":"91","author":"Figg","year":"2023","journal-title":"Proteins"},{"key":"10.1016\/j.biopha.2026.119443_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Eng."},{"key":"10.1016\/j.biopha.2026.119443_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103947","article-title":"Oxidative hypoxia drives TGF-\u03b21-induced fibrosis under normoxia","volume":"89","author":"Choi","year":"2026","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2026.119443_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2024.106224","article-title":"Oleic acid inhibits the migration and invasion of breast cancer cells with stemness characteristics through oxidative stress-mediated attenuation of the FAK\/AKT\/NF-\u03baB pathway","volume":"116","author":"Kim","year":"2024","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.biopha.2026.119443_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119443_bib45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/cancers13010130","article-title":"Flavonoids targeting HIF-1: Implications on cancer metabolism","volume":"13","author":"Samec","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119443_bib46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.foodres.2013.02.009","article-title":"A review on protein\u2013phenolic interactions and associated changes","volume":"51","author":"Ozdal","year":"2013","journal-title":"Food Res. Int."},{"key":"10.1016\/j.biopha.2026.119443_bib47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s12276-024-01221-2","article-title":"Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer","volume":"56","author":"Park","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119443_bib48","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/1878-0261.12682","article-title":"Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction","volume":"14","author":"Han","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2017.02.017","article-title":"Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells","volume":"321","author":"Tang","year":"2017","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.biopha.2026.119443_bib50","series-title":"vitro drug metabolism studies using human liver microsomes, in: Dosage Forms-Innovation and Future Perspectives","author":"Gajula","year":"2022"},{"key":"10.1016\/j.biopha.2026.119443_bib51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cts.13070","article-title":"Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers","volume":"15","author":"Yoshida","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119443_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2021.05.028","article-title":"vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review","volume":"335","author":"Fedi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119443_bib54","doi-asserted-by":"crossref","first-page":"16975","DOI":"10.1074\/jbc.M111.334466","article-title":"Expression of prolyl hydroxylases (PHDs) is selectively controlled by HIF-1 and HIF-2 proteins in nucleus pulposus cells of the intervertebral disc: Distinct roles of PHD2 and PHD3 proteins in controlling HIF-1\u03b1 activity in hypoxia","volume":"287","author":"Fujita","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119443_bib55","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/cancers13102309","article-title":"Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer","volume":"13","author":"Koren","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119443_bib56","article-title":"The cancer cell oxygen sensor","author":"Hern\u00e1ndez Fernaud","year":"2015","journal-title":"PHD2 Promot. Metastas-.-. via Act. Cancer-Assoc. fibroblasts"},{"key":"10.1016\/j.biopha.2026.119443_bib57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cbf.1732","article-title":"An activator of PHD2, KRH102140, decreases angiogenesis via inhibition of HIF-1\u03b1","volume":"29","author":"Nepal","year":"2011","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.biopha.2026.119443_bib58","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ajcn\/74.4.418","article-title":"Flavonoids: A review of probable mechanisms of action and potential applications","volume":"74","author":"Nijveldt","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.biopha.2026.119443_bib59","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/0008-5472.CAN-11-3600","article-title":"HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells","volume":"72","author":"Newman","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119443_bib60","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.1158\/0008-5472.CAN-05-1877","article-title":"Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors","volume":"65","author":"Ibrahim","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119443_bib61","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbrc.2004.04.125","article-title":"Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1): Structural requirement of bisphenol A for degradation of HIF-1\u03b1","volume":"318","author":"Kubo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119443_bib62","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","article-title":"ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine","volume":"48","author":"Juan-Carlos","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2026.119443_bib63","article-title":"Co-expression of HIF1A with multi-drug transporters (P-GP, MRP1, BCRP) in chemoresistant breast, colorectal, and ovarian cancer cells","volume":"23","author":"Nath","year":"2025","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119443_bib64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-004-0653-9","article-title":"Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications","volume":"131","author":"Berger","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119443_bib65","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.18632\/oncotarget.2806","article-title":"Hypoxia\/HIF1\u03b1 induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2","volume":"6","author":"Karakashev","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119443_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.06.060","article-title":"Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1\u03b1 synthesis in HT-29 colon cancer cells","volume":"398","author":"Shin","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119443_bib67","article-title":"Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119443_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119443_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1196\/annals.1391.004","article-title":"Oxygen, hypoxia, and stress","volume":"1113","author":"Taylor","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119443_bib70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119443_bib71","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.3390\/molecules28248096","article-title":"Specifics of Pharmacokinetics and Biodistribution of 5-Fluorouracil Polymeric Complex","volume":"28","author":"Zhukova","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119443_bib72","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00280-018-3749-7","article-title":"A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer","volume":"83","author":"Duska","year":"2019","journal-title":"Cancer Chemother. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:00:22Z","timestamp":1787439622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":71,"alternative-id":["S0753332226004798"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119443","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic activation of PHD2 sensitizes non\u2013small cell lung cancer cells to osimertinib","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119443"}}